Antimalarial drugs: Modes of action and mechanisms of parasite resistance

Future Microbiology

Volumn 5, Issue 12, 2010, Pages 1857-1873

  Müller, Ingrid B ^a   Hyde, John E ^b  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b NONE

Author keywords

Antifolate; Artemisinin; Atovaquone; Gene polymorphism; Parasite drug resistance; Quinoline

Indexed keywords

4 AMINOQUINOLINE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; CYCLOGUANIL; DIHYDROARTEMISININ; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; GLUTATHIONE; HALOFANTRINE; MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN 1; PIPERAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; SULFADOXINE; SULFONAMIDE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CHROMOSOME 1; CINCHONA; DRUG EFFICACY; DRUG SAFETY; GENE INACTIVATION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; MALARIA; NONHUMAN; PARASITE INCIDENCE; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; TANZANIA;

ANTIMALARIALS; ARTEMISININS; ATOVAQUONE; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; HUMANS; MALARIA; PLASMODIUM FALCIPARUM; QUINOLINES;

PLASMODIUM FALCIPARUM;

EID: 78650486233     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.136     Document Type: Review

References (189)

1. Sutherland CJ, Tanomsing N, Nolder D et al.: Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J. Inf. Dis. 201(10), 1544-1550 (2010).
2. White NJ: Plasmodium knowlesi: the fifth human malaria parasite. Clin. Infect. Dis. 46(2), 172-173 (2008).
3. Cox-Singh J: Malaria: what can apes teach humans? Future Microbiol. 5(8), 1157-1160 (2010).
4. Greenwood BM, Fidock DA, Kyle DE et al.: Malaria: progress, perils, and prospects for eradication. J. Clin. Inv. 118(4), 1266-1276 (2008).
5. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW: The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 4(6), 327-336 (2004).
6. Ballou RW: The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 31(9), 492-500 (2009).
7. Casares S, Brumeanu TD, Richie TL: The RTS,S malaria vaccine. Vaccine 28(31), 4880-4894 (2010).
8. DAlessandro U: Existing antimalarial agents and malaria-treatment strategies. Expert Opinion Pharmacother. 10(8), 1291-1306 (2009).
9. Olliaro P, Wells TNC: The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Therap. 85(6), 584-595 (2009).
10. Ekland EH, Fidock DA: Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opin. Microbiol. 10(4), 363-370 (2007).
11. Hayton K, Su XZ: Drug resistance and genetic mapping in Plasmodium falciparum. Curr. Genet. 54(5), 223-239 (2008).
12. Dharia NV, Sidhu ABS, Cassera MB et al.: Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10(2), R21 (2009).
13. Mu JB, Myers RA, Jiang HY et al.: Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nature Genet. 42(3), 268-271 (2010).
14. Fitch CD: Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 74(16), 1957-1972 (2004).
15. Payne D: Spread of chloroquine resistance in Plasmodium falciparum. Parasitol. Today 3(8), 241-246 (1987).
16. Wellems TE, Plowe CV: Chloroquine-resistant malaria. J. Inf. Dis. 184(6), 770-776 (2001).
17. Kuhn Y, Rohrbach P, Lanzer M: Quantitative pH measurements in Plasmodium falciparum-infected erythrocytes using pHluorin. Cell. Microbiol. 9(4), 1004-1013 (2007).
18. Klonis N, Dilanian R, Hanssen E et al.: Hematin-hematin self-association states involved in the formation and reactivity of the malaria parasite pigment, hemozoin. Biochemistry 49(31), 6804-6811 (2010).
19. Warhurst DC: Understanding resistance to antimalarial 4-aminoquinolines, cinchona alkaloids and the highly hydrophobic arylaminoalcohols. Curr. Science 92(11), 1556-1560 (2007).
20. Roepe PD: Molecular and physiologic basis of quinoline drug resistance in Plasmodium falciparum malaria. Future Microbiol. 4(4), 441-455 (2009).
21. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K: Chloroquine transport via the malaria parasites chloroquine resistance transporter. Science 325(5948), 1680-1682 (2009).
22. Cabrera M, Paguio MF, Xie CA, Roepe PD: Reduced digestive vacuolar accumulation of chloroquine is not linked to resistance to chloroquine toxicity. Biochemistry 48(47), 11152-11154 (2009).
23. Fidock DA, Nomura T, Talley AK et al.: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6, 861-871 (2000).
24. Wellems TE, Walker-Jonah A, Panton LJ: Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc. Natl Acad. Sci. USA 88(8), 3382-3386 (1991).
25. Cooper RA, Hartwig CL, Ferdig MT: pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective. Acta Trop. 94(3), 170-180 (2005).
26. Sidhu ABS, Verdier-Pinard D, Fidock DA: Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298(5591), 210-213 (2002).
27. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA: Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol. Microbiol. 56(2), 323-333 (2005).
28. Martin RE, Kirk K: The malaria parasites chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily. Mol. Biol. Evol. 21(10), 1938-1949 (2004).
29. Tran CV, Saier MH: The principal chloroquine resistance protein of Plasmodium falciparum is a member of the drug/metabolite transporter superfamily. Microbiology 150(1), 1-3 (2004).
30. Nomura T, Carlton JMR, Baird JK et al.: Evidence for different mechanisms of chloroquine resistance in 2 plasmodium species that cause human malaria. J. Inf. Dis. 183(11), 1653-1661 (2001).
31. Hunt P, Cravo PVL, Donleavy P, Carlton JMR, Walliker D: Chloroquine resistance in Plasmodium chabaudi: are chloroquine-resistance transporter (crt) and multi-drug resistance (mdr1) orthologues involved? Mol. Biochem. Parasitol. 133(1), 27-35 (2004).
32. Witkowski B, Berry A, Benoit-Vical F: Resistance to antimalarial compounds: methods and applications. Drug Resist. Updates 12(1-2), 42-50 (2009).
33. Djimde A, Doumbo OK, Cortese JF et al.: A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344(4), 257-263 (2001).
34. Contreras CE, Cortese JF, Caraballo A, Plowe CV: Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. Am. J. Trop. Med. Hyg. 67(4), 400-405 (2002).
35. Durrand V, Berry A, Sem R, Glaziou P, Beaudou J, Fandeur T: Variations in the sequence and expression of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and their relationship to chloroquine resistance in vitro. Mol. Biochem. Parasitol. 136(2), 273-285 (2004).
36. Rungsihirunrat K, Chaijareonkul W, Seugorn A, Na-Bangchang K, Thaithong S: Association between chloroquine resistance phenotypes and point mutations in pfcrt and pfmdr1 in Plasmodium falciparum isolates from Thailand. Acta Trop. 109(1), 37-40 (2009).
37. Lakshmanan V, Bray PG, Verdier-Pinard D et al.: A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24(13), 2294-2305 (2005).
38. Valderramos SG, Valderramos J-C, Musset L et al.: Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PloS Path. 6(5), E1000887 (2010).
39. Valderramos SG, Fidock DA: Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci. 27(11), 594-601 (2006).
40. Johnson DJ, Fidock DA, Mungthin M et al.: Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol. Cell 15(6), 867-877 (2004).
41. Bray PG, Mungthin M, Hastings IM et al.: PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol. Microbiol. 62(1), 238-251 (2006).
42. van Schalkwyk DA, Egan TJ: Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist. Updates 9(4-5), 211-226 (2006).
43. Henry M, Alibert S, Rogier C, Barbe J, Pradines B: Inhibition of efflux of quinolines as new therapeutic strategy in malaria. Curr. Top. Med. Chem. 8(7), 563-578 (2008).
44. Paguio MF, Cabrera M, Roepe PD: Chloroquine transport in Plasmodium falciparum. 2. Analysis of pfcrt-mediated drug transport using proteoliposomes and a fluorescent chloroquine probe. Biochemistry 48(40), 9482-9491 (2009).
45. Cabrera M, Natarajan J, Paguio MF, Wolf C, Urbach JS, Roepe PD: Chloroquine transport in Plasmodium falciparum. 1. Influx and efflux kinetics for live trophozoite parasites using a novel fluorescent chloroquine probe. Biochemistry 48(40), 9471-9481 (2009).
46. Hayward R, Saliba KJ, Kirk K: The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance. J. Cell Sci. 119(6), 1016-1025 (2006).
47. Gligorijevic B, Bennett T, McAllister R, Urbach JS, Roepe PD: Spinning disk confocal microscopy of live, intraerythrocytic malarial parasites. 2. Altered vacuolar volume regulation in drug resistant malaria. Biochemistry 45(41), 12411-12423 (2006). (Pubitemid 44583684)
48. Lehane AM, Kirk K: Chloroquine resistance-conferring mutations in pfcrt give rise to a chloroquine-associated H+ leak from the malaria parasites digestive vacuole. Antimicrob. Agents Chemoth. 52(12), 4374-4380 (2008).
49. Zhang HB, Paguio M, Roepe PD: The antimalarial drug resistance protein Plasmodium falciparum chloroquine resistance transporter binds chloroquine. Biochemistry 43(26), 8290-8296 (2004).
50. Cooper RA, Lane KD, Deng BB et al.: Mutations in transmembrane domains 1, 4 and 9 of the Plasmodium falciparum chloroquine resistance transporter alter susceptibility to chloroquine, quinine and quinidine. Mol. Microbiol. 63(1), 270-282 (2007).
51. Duraisingh MT, Cowman AF: Contribution of the pfmdr1 gene to antimalarial drug resistance. Acta Trop. 94(3), 181-190 (2005).
52. Ferdig MT, Cooper RA, Mu JB et al.: Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52(4), 985-997 (2004).
53. Henry M, Briolant S, Zettor A et al.: Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob. Agents Chemoth. 53(5), 1926-1930 (2009).
54. Nkrumah LJ, Riegelhaupt PM, Moura P et al.: Probing the multifactorial basis of Plasmodium falciparum quinine resistance: Evidence for a strain-specific contribution of the sodium-proton exchanger PfNHE. Mol. Biochem. Parasitol. 165(2), 122-131 (2009).
55. Rohrbach P, Sanchez CP, Hayton K et al.: Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J. 25(13), 3000-3011 (2006).
56. Sanchez CP, Rotmann A, Stein WD, Lanzer M: Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Mol. Microbiol. 70(4), 786-798 (2008).
57. Pleeter P, Lekostaj JK, Roepe PD: Purified Plasmodium falciparum multi-drug resistance protein (PfMDR 1) binds a high affinity chloroquine analogue. Mol. Biochem. Parasitol. 173(2), 158-161 (2010).
58. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF: Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403(6772), 906-909 (2000).
59. Sidhu ABS, Valderramos SG, Fidock DA: pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 57(4), 913-926 (2005).
60. Mehlotra RK, Mattera G, Bockarie MJ et al.: Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob. Agents Chemoth. 52(6), 2212-2222 (2008).
61. Sa JM, Twu O, Hayton K et al.: Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc. Natl Acad. Sci. USA 106(45), 18883-18889 (2009).
62. Chen NH, Russell B, Fowler E, Peters J, Cheng Q: Levels of chloroquine resistance in Plasmodium falciparum are determined by loci other than pfcrt and pfmdr1. J. Inf. Dis. 185(3), 405-406 (2002).
63. Jiang HY, Patel JJ, Yi M et al.: Genome-wide compensatory changes accompany drug-selected mutations in the Plasmodium falciparum crt gene. PloS One 3(6), E2484 (2008).
64. Müller S: Redox and antioxidant systems of the malaria parasite Plasmodium falciparum. Mol. Microbiol. 53(5), 1291-1305 (2004).
65. Price RN, Uhlemann AC, Brockman A et al.: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364(9432), 438-447 (2004).
66. Sidhu ABS, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA: Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Inf. Dis. 194(4), 528-535 (2006).
67. Alker AP, Lim P, Sem R et al.: PFMDR1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med. Hyg. 76(4), 641-647 (2007).
68. Uhlemann AC, McGready R, Ashley EA et al.: Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J. Inf. Dis. 195(1), 134-141 (2007).
69. Waller KL, Muhle RA, Ursos LM et al.: Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J. Biol. Chem. 278(35), 33593-33601 (2003).
70. Sanchez CP, Stein WD, Lanzer M: Dissecting the components of quinine accumulation in Plasmodium falciparum. Mol. Microbiol. 67(5), 1081-1093 (2008).
71. Bennett TN, Patel J, Ferdig MT, Roepe PD: Plasmodium falciparum Na+/H+ exchanger activity and quinine resistance. Mol. Biochem. Parasitol. 153(1), 48-58 (2007).
72. Andriantsoanirina V, Menard D, Rabearimanana S et al.: Association of microsatellite variations of Plasmodium falciparum Na+/H+ exchanger (pfnhe-1) gene with reduced in vitro susceptibility to quinine: lack of confirmation in clinical isolates from Africa. Am. J. Trop. Med. Hyg. 82(5), 782-787 (2010).
73. Okombo J, Kiara SM, Rono J et al.: In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrob. Agents Chemoth. 54(8), 3302-3307 (2010).
74. Meng H, Zhang R, Yang H et al.: In vitro Sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger. Antimicrob. Agents Chemother. 54(10), 4306-4313 (2010).
75. Kavishe RA, van den Heuvel JMW, van de Vegte-Bolmer M, Luty AJF, Russel FGM, Koenderink JB: Localization of the ATP-binding cassette (ABC) transport proteins PfMRP1, PfMRP2, and PfMDR5 at the Plasmodium falciparum plasma membrane. Malaria J. 8, 205 (2009).
76. Raj DK, Mu JB, Jiang HY et al.: Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J. Biol. Chem. 284(12), 7687-7696 (2009).
77. Dahlstrom S, Ferreira PE, Veiga MI et al.: Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J. Inf. Dis. 200(9), 1456-1464 (2009).
78. Sisowath C, Petersen I, Veiga MI et al.: In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Inf. Dis. 199(5), 750-757 (2009).
79. Mu JB, Ferdig MT, Feng XR et al.: Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol. 49(4), 977-989 (2003).
80. Koenderink JB, Kavishe RA, Rijpma SR, Russel FGM: The ABCs of multidrug resistance in malaria. Trends Parasitol. 26(9), 440-446 (2010).
81. Hyde JE: Drug-resistant malaria - an insight. FEBS J. 274(18), 4688-4698 (2007).
82. White NJ: Qinghaosu (Artemisinin): the price of success. Science 320(5874), 330-334 (2008).
83. Warsame M, Olumese P, Mendis K: Role of medicines in malaria control and elimination. Drug Deveopl. Res. 71(1), 4-11 (2010).
84. Mkulama MAP, Chishimba S, Sikalima J, Rouse P, Thuma PE, Mharakurwa S: Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia. Malaria J. 7, 87 (2008).
85. Hyde JE: Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 4(2), 165-174 (2002).
86. Gregson A, Plowe CV: Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57(1), 117-145 (2005).
87. Pearce RJ, Pota H, Evehe MSB et al.: Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PloS Med. 6(4), E1000055 (2009).
88. Naidoo I, Roper C: Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. Trends Parasit. 26(9), 447-456 (2010).
89. Kublin JG, Dzinjalamala FK, Kamwendo DD et al.: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Inf. Dis. 185(3), 380-388 (2002).
90. Malamba S, Sandison T, Lule J et al.: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am. J. Trop. Med. Hyg. 82(5), 766-771 (2010).
91. Raman J, Little F, Roper C et al.: Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo province, southern Mozambique. Am. J. Trop. Med. Hyg. 82(5), 788-794 (2010).
92. Nzila A, Ochong E, Nduati E et al.: Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans. Roy. Soc. Trop. Med. Hyg. 99(5), 341-346 (2005).
93. Hyde JE: Antifolate resistance in Africa and the 164-dollar question. Trans. Roy. Soc. Trop. Med. Hyg. 102(4), 301-303 (2008).
94. Sibley CH, Hyde JE, Sims PFG et al.: Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17(12), 582-588 (2001).
95. McCollum AM, Poe AC, Hamel M et al.: Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J. Inf. Dis. 194(2), 189-197 (2006).
96. Kiara SM, Okombo J, Masseno V et al.: In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-64-Leu mutation. Antimicrob. Agents Chemoth. 53(9), 3793-3798 (2009).
97. Karema C, Imwong M, Fanello CI et al.: Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrob. Agents Chemoth. 54(1), 477-483 (2010).
98. Ochong E, Bell DJ, Johnson DJ et al.: Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. Antimicrob. Agents Chemoth. 52(11), 3883-3888 (2008).
99. Cortese JF, Plowe CV: Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol. Biochem. Parasitol. 94(2), 205-214 (1998).
100. Lozovsky ER, Chookajorn T, Brown KM et al.: Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc. Natl Acad. Sci. USA 106(29), 12025-12030 (2009).
101. Sandefur CI, Wooden JM, Quaye IK, Sirawaraporn W, Sibley CH: Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro. Mol. Biochem. Parasitol. 154(1), 1-5 (2007).
102. Kidgell C, Volkman SK, Daily J et al.: A systematic map of genetic variation in Plasmodium falciparum. PloS Pathog. 2(6), 562-577 (2006).
103. Nair S, Miller B, Barends M et al.: Adaptive copy number evolution in malaria parasites. PloS Genet. 4(10), E1000243 (2008).
104. Hastings IM: Malaria control and the evolution of drug resistance: an intriguing link. Trends Parasitol. 19(2), 70-73 (2003).
105. Peterson DS, Milhous WK, Wellems TE: Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl Acad. Sci. USA 87(8), 3018-3022 (1990).
106. Foote SJ, Galatis D, Cowman AF: Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl Acad. Sci. USA 87(8), 3014-3017 (1990).
107. Brooks DR, Wang P, Read M, Watkins WM, Sims PFG, Hyde JE: Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase - dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224(2), 397-405 (1994).
108. Triglia T, Cowman AF: Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 91(15), 7149-7153 (1994).
109. Triglia T, Menting JGT, Wilson C, Cowman AF: Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 94(25), 13944-13949 (1997).
110. Wang P, Lee CS, Bayoumi R et al.: Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol. Biochem. Parasitol. 89(2), 161-177 (1997).
111. Sutherland CJ, Fifer H, Pearce RJ et al.: Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom. Antimicrob. Agents Chemoth. 53(8), 3405-3410 (2009).
112. Lumb V, Das MK, Mittra P et al.: Emergence of an unusual sulfadoxine-pyrimethamine resistance pattern and a novel K540N mutation in dihydropteroate synthetase in Plasmodium falciparum isolates obtained from Car Nicobar island, India, after the 2004 tsunami. J. Inf. Dis. 199(7), 1064-1073 (2009).
113. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S et al.: Insights into antifolate resistance from malarial DHFR-TS structures. Nature Struct. Biol. 10(5), 357-365 (2003).
114. Dasgupta T, Chitnumsub P, Kamchonwongpaisan S et al.: Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria. ACS Chem. Biol. 4(1), 29-40 (2009).
115. Yuthavong Y, Kamchonwongpaisan S, Leartsakulpanich U, Chitnumsub P: Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol. 1(1), 113-125 (2006).
116. Calzada JE, Samudio F, Bayard V, Obaldia N, de Mosca IB, Pascale JM: Revising antimalarial drug policy in Central America: experience in Panama. Trans. Roy. Soc. Trop. Med. Hyg. 102(7), 694-698 (2008).
117. Adane L, Patel DS, Bharatam PV: Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition. Chem. Biol. Drug Design 75(1), 115-126 (2010).
118. de Beer TAP, Louw AI, Joubert F: Elucidation of sulfadoxine resistance with structural models of the bifunctional Plasmodium falciparum dihydropterin pyrophosphokinase-dihydropteroate synthase. Bioorg. Med. Chem. 14(13), 4433-4443 (2006).
119. Dzinjalamala FK, Macheso A, Kublin JG et al.: Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 72(3), 267-272 (2005).
120. van Eijk AM, Ouma PO, Williamson J et al.: Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in western Kenya who have uncomplicated malaria. J. Inf. Dis. 198(10), 1550-1553 (2008).
121. Wang P, Brobey RKB, Horii T, Sims PFG, Hyde JE: Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol. Microbiol. 32(6), 1254-1262 (1999).
122. Wang P, Wang Q, Sims PFG, Hyde JE: Characterisation of exogenous folate transport in Plasmodium falciparum. Mol. Biochem. Parasitol. 154(1), 40-51 (2007).
123. Dahlstrom S, Veiga MI, Martensson A, Bjorkman A, Gil JP: Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment. Antimicrob. Agents Chemoth. 53(6), 2553-2556 (2009).
124. Cui LW, Su XZ: Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev. Anti-Inf. Ther. 7(8), 999-1013 (2009).
125. Eastman RT, Fidock DA: Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Rev. Microbiol. 7(12), 864-874 (2009).
126. Tshefu AK, Gaye O, Kayentao K et al.: Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether- lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375(9724), 1457-1467 (2010).
127. Beshir K, Sutherland CJ, Merinopoulos I et al.: Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76. Antimicrob. Agents Chemoth. 54(9), 3714-3716 (2010).
128. Nosten F, White NJ: Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77(6), 181-192 (2007).
129. Briolant S, Henry M, Oeuvray C et al.: Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob. Agents Chemoth. 54(9), 3537-3544 (2010).
130. Jansen FH: The pharmaceutical death-ride of dihydroartemisinin. Malaria J. 9, 212 (2010).
131. Fidock DA: Drug discovery: priming the antimalarial pipeline. Nature 465(7296), 297-298 (2010).
132. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE: Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36(14), 1427-1441 (2006).
133. Robert A, Benoit-Vical F, Claparols C, Meunier B: The antimalarial drug artemisinin alkylates heme in infected mice. Proc. Natl Acad. Sci. USA 102(38), 13676-13680 (2005).
134. Asawamahasakda W, Ittarat I, Pu YM, Ziffer H, Meshnick SR: Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemoth. 38(8), 1854-1858 (1994).
135. Bhisutthibhan J, Pan XQ, Hossler PA et al.: The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J. Biol. Chem. 273(26), 16192-16198 (1998).
136. Wang J, Huang L, Li J et al.: Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 5(3), E9582 (2010).
137. Mannan A, Liu CZ, Arsenault PR et al.: DMSO triggers the generation of ROS leading to an increase in artemisinin and dihydroartemisinic acid in Artemisia annua shoot cultures. Plant Cell Rep. 29(2), 143-152 (2010).
138. ONeill PM, Barton VE, Ward SA: The molecular mechanism of action of artemisinin - the debate continues. Molecules 15(3), 1705-1721 (2010).
139. Hartwig CL, Rosenthal AS, DAngelo J, Griffin CE, Posner GH, Cooper RA: Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem. Pharmacol. 77(3), 322-336 (2009).
140. Garcia-Pineres AJ, Castro V, Mora G et al.: Cysteine 38 in p65/NF-kB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 276(43), 39713-39720 (2001).
141. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N: What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 15(15-16), 668-678 (2010).
142. Eckstein-Ludwig U, Webb RJ, Van Goethem ID et al.: Artemisinins target the SERCA of Plasmodium falciparum. Nature 424(6951), 957-961 (2003).
143. Uhlemann AC, Cameron A, Eckstein-Ludwig U et al.: A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol. 12(7), 628-629 (2005).
144. Afonso A, Hunt P, Cheesman S et al.: Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 50(2), 480-489 (2006).
145. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S: Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob. Agents Chemother. 54(9), 3842-3852 (2010).
146. Dondorp AM, Nosten F, Yi P et al.: Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361(5), 455-467 (2009).
147. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359(24), 2619-2620 (2008).
148. Samarasekera U: Countries race to contain resistance to key antimalarial. Lancet 374(9686), 277-280 (2009).
149. Anderson TJC, Nair S, Nkhoma S et al.: High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J. Inf. Dis. 201(9), 1326-1330 (2010).
150. Imwong M, Dondorp AM, Nosten F et al.: Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob. Agents Chemoth. 54(7), 2886-2892 (2010).
151. Wootton JC, Feng XR, Ferdig MT et al.: Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418(6895), 320-323 (2002).
152. Thanh NV, Toan TQ, Cowman AF et al.: Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malaria J. 9, 181 (2010).
153. Müller O, Sie A, Meissner P, Schirmer RH, Kouyate B: Artemisinin resistance on the Thai-Cambodian border. Lancet 374(9699), 1419 (2009).
154. Walker DJ, Pitsch JL, Peng MM et al.: Mechanisms of artemisinin resistance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob. Agents Chemoth. 44(2), 344-347 (2000).
155. MacDonald SM, Bhisutthibhan J, Shapiro TA et al.: Immune mimicry in malaria: Plasmodium falciparum secretes a functional histamine-releasing factor homolog in vitro and in vivo. Proc. Natl Acad. Sci. USA 98(19), 10829-10832 (2001).
156. Ferrer-Rodriguez I, Perez-Rosado J, Gervais GW, Peters W, Robinson BL, Serrano AE: Plasmodium yoelii: identification and partial characterization of an MDR1 gene in an artemisinin-resistant line. J. Parasitol. 90(1), 152-160 (2004).
157. Gutteridge WE: Antimalarial drugs currently in development. J. Roy. Soc. Med. 82(Suppl. 17), 63-66 (1989).
158. Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem. 272(7), 3961-3966 (1997).
159. Kessl JJ, Ha KH, Merritt AK et al.: Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J. Biol. Chem. 280(17), 17142-17148 (2005).
160. Mather MW, Darrouzet E, Valkova-Valchanova M et al.: Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J. Biol. Chem. 280(29), 27458-27465 (2005).
161. Clyde DF: Treatment of drug-resistant malaria in man. Bull. World Health Organ. 50(3-4), 243-249 (1974).
162. Korsinczky M, Chen NH, Kotecka B, Saul A, Rieckmann K, Cheng Q: Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemoth. 44(8), 2100-2108 (2000).
163. Berry A, Senescau A, Lelievre J et al.: Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans. Roy. Soc. Trop. Med. Hyg. 100(10), 986-988 (2006).
164. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB: Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33(4), 704-711 (1999).
165. Srivastava IK, Vaidya AB: A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemoth. 43(6), 1334-1339 (1999).
166. Painter HJ, Morrisey JM, Mather MW, Vaidya AB: Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446(7131), 88-91 (2007).
167. Wichmann O, Muehlberger N, Jelinek T et al.: Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J. Inf. Dis. 190(9), 1541-1546 (2004).
168. Happi CT, Gbotosho GO, Folarin OA et al.: Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malaria J. 5,82 (2006).
169. Afonso A, Neto Z, Castro H et al.: Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene. Malaria J. 9, 135 (2010).
170. Sutherland CJ, Laundy M, Price N et al.: Mutations in the Plasmodium
171. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P: A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria J. 8, 89 (2009)
172. Sridaran S, McClintock SK, Syphard LM, Herman KM, Barnwell JW, Udhayakumar V: Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malaria J. 9, 247 (2010).
173. Edwards G, Biagini GA: Resisting resistance: dealing with the irrepressible problem of malaria. Brit. J. Clin. Pharmacol. 61(6), 690-693 (2006).
174. Walsh JJ, Coughlana D, Heneghan N, Gaynor C, Bell A: A novel artemisinin-quinine hybrid with potent antimalarial activity. Bioorg. Med. Chem. Lett. 17(13), 3599-3602 (2007).
175. Walsh JJ, Bell A: Hybrid drugs for malaria. Curr. Pharmaceut. Design 15(25), 2970-2985 (2009).
176. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV: Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl Acad. Sci. USA 94(4), 1124-1129 (1997).
177. Hastings MD, Sibley CH: Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc. Natl Acad. Sci. USA 99(20), 13137-13141 (2002).
178. Japrung D, Leartsakulpanich U, Chusacultanachai S, Yuthavong Y: Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination. Antimicrob. Agents Chemoth. 51(12), 4356-4360 (2007).
179. Laufer MK, Thesing PC, Eddington ND et al.: Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355(19), 1959-1966 (2006).
180. Mwai L, Ochong E, Abdirahman A et al.: Chloroquine resistance before and after its withdrawal in Kenya. Malaria J. 8, 106 (2009).
181. Alifrangis M, Lemnge MM, Ronn AM et al.: Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets. Am. J. Trop. Med. Hyg. 69(3), 238-243 (2003).
182. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA: Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob. Agents Chemoth. 51(6), 2085-2091 (2007).
183. Marks F, Evans J, Meyer CG et al.: High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti Region of Ghana. Antimicrob. Agents Chemoth. 49(3), 1101-1105 (2005).
184. Mendez F, Herrera S, Murrain B et al.: Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. Am. J. Trop. Med. Hyg. 77(3), 438-443 (2007).
185. Gamo FJ, Sanz LM, Vidal J et al.: Thousands of chemical starting points for antimalarial lead identification. Nature 465(7296), 305-310 (2010).
186. Guiguemde WA, Shelat AA, Bouck D et al.: Chemical genetics of Plasmodium falciparum. Nature 465(7296), 311-315 (2010).
187. McFadden GI, Roos DS: Apicomplexan plastids as drug targets. Trends Microbiol. 7(8), 328-333 (1999).
188. Dahl EL, Rosenthal PJ: Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol. 24(6), 279-284 (2008).
189. World Health Organization: World Malaria Report (2009) http://whqlibdoc.who.int publications/ 2009/9789241563901-eng.pdf